SciTech Development, Inc.

SciTech Development, Inc. A clinical-stage, specialty oncology pharmaceutical company Revolutionizing how safe and promising yet challenged drugs can be delivered to kill cancer ST-001 nanoFenretinide: Lead Drug Candidate in Clinical Trials With innovative science and advanced nanotechnology, SciTech has developed ST-001 nanoFenretinide, a patented new drug with clinical trials in progress for T-cell lymphoma (a form of non-Hodgkin lymphoma). FDA has granted Orphan Drug Designation, allowing 7 years of market exclusivity once approved. ST-001 Clinical Trials Update ► Confirmed partial response and stable disease observed ► Preliminary data supports that ST-001 is safe and tolerable at escalating dose levels and has shown efficient delivery of therapeutic doses ► Trial completion for Phase 1a accelerated is targeted for December 2024 ► Small cell lung cancer trial expected to begin Q2 2025 ► NCI provided additional ~$1M gratis supply of fenretinide to dose 300+ patients, complete Phase 1a/b trials, and expand clinical trials"